20-F: Scinai Immunotherapeutics Faces Going Concern Doubt Amid R&D Pivot

Scinai Immunotherapeutics reports continued operating losses and substantial doubt about its ability to continue as a going concern, despite growing CDMO revenues and strategic R&D advancements.

Summary

• Scinai Immunotherapeutics Ltd. operates two business units: Scinai R&D, focused on inflammation and immunology therapeutics (PC111 program and NanoAbs platform), and a Contract Development and Manufacturing Organization (CDMO) business.
• The company reported a net loss of $8.3 million for the year ended December 31, 2025, compared to a net income of $4.8 million in 2024, with the 2024 income primarily due to a one-time $14.8 million gain from a loan conversion.
• Revenues from CDMO activities increased to $1.3 million in 2025 from $0.7 million in 2024, reflecting expansion, but these revenues are not yet sufficient to cover operating expenses.
• Research and development expenses decreased to $2.4 million in 2025 from $5.6 million in 2024, mainly due to a decrease in employee and facility allocation to the R&D unit.
• Cash and cash equivalents totaled $1.6 million as of December 31, 2025, down from $1.9 million in 2024, with negative cash flows from operating activities of $6.0 million in 2025.
• The company's current cash position is insufficient to fund planned operations for at least one year, raising substantial doubt about its ability to continue as a going concern.
• Scinai acquired Recipharm Israel Ltd. (now Scinai Biopharma Services Ltd.) in February 2026, expanding its CDMO capabilities to include small-molecule manufacturing and entering a strategic commercial collaboration with Recipharm.
• An option agreement to acquire Pincell S.r.l., owner of PC111 (a monoclonal antibody for severe dermatological conditions), was amended in February 2026, extending the option conditions fulfillment deadline to August 31, 2026, and the exercise date to September 30, 2026.
• The initial grant application for €12 million under the European Funds for a Modern Economy (FENG) program to fund PC111 development was rejected, and a revised application was submitted in March 2026.
• The IL-17 NanoAb program is being reassessed due to scientific, technical, and market considerations, including the competitive landscape, with two product profiles (intradermal and bispecific) under evaluation.
• Scinai received a non-dilutive grant of approximately $310,000 from the Israel Innovation Authority (IIA) in February 2026 to fund 66% of a project for an advanced fill-and-finish system for sterile manufacturing.
• The company has faced Nasdaq non-compliance notices regarding minimum bid price and stockholders' equity, which were addressed through a reverse ADS split and conversion of EIB loan into preferred shares, respectively.
• A proposed Nasdaq rule change could lead to immediate delisting if the market value of listed securities falls below $5 million for 30 consecutive business days, with no cure period or appeal.
• The company's operations are primarily in Israel, exposing it to geopolitical, security, and economic risks, including ongoing conflicts in the region.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the explicit 'going concern' qualification, continued operating losses, and reliance on future capital raises, despite some positive strategic developments and revenue growth in the CDMO unit.

Positives

• CDMO revenues increased to $1.3 million in 2025 from $0.7 million in 2024, demonstrating growth in the new business unit.
• Acquisition of Recipharm Israel Ltd. (now Scinai Biopharma Services Ltd.) in February 2026 expands CDMO capabilities to include small-molecule manufacturing and strengthens industrial credibility.
• Strategic commercial collaboration with Recipharm provides access to a global manufacturing network and potential downstream economics for client programs.
• PC111, a lead clinical asset, has received Orphan Drug Designation from the European Medicines Agency for pemphigus, potentially offering expedited regulatory pathways.
• Received a non-dilutive grant of approximately $310,000 from the Israel Innovation Authority (IIA) in February 2026 for an advanced fill-and-finish system.
• Successfully regained compliance with Nasdaq's minimum bid price rule through a 1-for-10 reverse ADS split in May 2024.
• Regained compliance with Nasdaq's minimum stockholders' equity rule in August 2024 by converting a significant portion of the EIB loan into preferred shares.
• The EIB loan restructuring in August 2024 converted approximately $29 million of debt into preferred shares, significantly reducing outstanding debt and eliminating interest accrual and royalty obligations on capital raises.
• The NanoAbs platform offers a pipeline of novel therapeutics targeting clinically validated pathways, with exclusive options to license additional candidates like IL-13 and TSLP.

Negatives

• Reported a net loss of $8.3 million for the year ended December 31, 2025, a significant decrease from the net income of $4.8 million in 2024 (which was driven by a one-time gain).
• Operating losses continued, totaling $7.5 million in 2025 and $8.6 million in 2024.
• Negative cash flows from operating activities persisted, with $6.0 million used in 2025 and $6.3 million in 2024.
• Current cash and cash equivalents of $1.6 million as of December 31, 2025, are insufficient to fund planned operations for at least one year, leading to a 'going concern' qualification.
• The initial grant application for €12 million under the FENG program to fund PC111 development was rejected, requiring a revised application and delaying funding certainty.
• The IL-17 NanoAb program's development strategy is under ongoing evaluation due to scientific, technical, and market considerations, indicating potential delays or changes in direction.
• Suspended active development of the COVID-19 NanoAb program due to changing market conditions and reduced funding interest, leading to abandonment of related patents.
• The CDMO business unit currently operates at a loss, as revenues do not yet cover base operating expenses and scale-up costs.
• Two executive officers, Dr. Tamar Ben-Yedidia (former CSO) and Dr. Dalit Weinstein Fischer (former CTO), resigned in 2025.

Risks

• Substantial additional financing is required to fund operations and development programs; inability to obtain it could lead to delays, reductions, or termination of activities, or cessation of operations.
• History of operating losses and no current profitability; may continue to incur losses and not achieve profitability in the near future or at all.
• Failure to meet Nasdaq's continued listing requirements could result in delisting of ADSs, adversely affecting market liquidity and price.
• The business strategy of combining CDMO and therapeutic pipeline development may not be successful, requiring effective resource management and efficient scaling.
• CDMO business success depends on market demand, ability to attract/retain customers, execute contracts, and deliver high-quality services on time, with risks from customer credit, program delays, and demand variability.
• CDMO operations are complex and subject to strict regulatory and quality requirements (cGMP); failure to comply could harm reputation and business.
• Dependence on third parties and collaborators for product candidate development, commercialization, and marketing; may be unsuccessful in forming or maintaining such relationships.
• Product candidates are at an early stage of development and do not generate revenue; may not be successful in discovering, developing, or commercializing any candidates.
• Clinical trials are expensive, time-consuming, and uncertain; delays or failures could adversely affect the business.
• Results from earlier preclinical or clinical studies may not be predictive of future results.
• Significant competition in both therapeutic development and CDMO business from larger, well-established companies with greater resources.
• NanoAbs programs depend on licenses from third parties (MPG and UMG); loss of rights due to non-compliance with terms could materially adversely affect the business.
• Ability to operate depends on continued operation of manufacturing facilities in Jerusalem and Yavne; disruptions could adversely affect operations.
• Raising additional capital may cause dilution to existing shareholders; debt financing may impose restrictive covenants.
• IL-17 program is subject to significant contractual, development, and strategic uncertainties, including IND submission deadlines and reassessment of development strategy.
• NanoAbs represent a relatively new approach, requiring overcoming significant challenges in development, commercialization, and manufacturing, with regulatory agencies potentially lacking experience in evaluation.
• Inability to exercise the option to acquire Pincell, or being required to resell Pincell shares if IND application for PC111 is not filed by December 31, 2028, will affect future prospects.
• Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy is required; failure could delay or prevent approval.
• Current and future product candidates would be subject to extensive regulation and may never obtain regulatory approval.
• Product candidates, if approved, will remain subject to ongoing regulatory requirements; failure to comply could lead to loss of approvals or suspension of sales.
• Product candidates, if approved, may face competition sooner than anticipated, including from biosimilar products and changes in regulatory exclusivity frameworks.
• Delays in future clinical trials due to various factors (e.g., participant enrollment, safety issues, manufacturing failures) would increase costs and delay revenue generation.
• Occurrence of serious complications or side effects in clinical trials or post-approval could impede trials, lead to refusal of approval, or revocation of marketing authorizations.
• Inadequate funding, resource constraints, or shifting priorities at regulatory authorities may delay development and approval.
• Coverage and reimbursement may not be available for product candidates, making profitable sales difficult.
• Current and future healthcare legislation and pricing regulations may adversely affect ability to obtain approval, commercialize, and achieve profitability.
• Subject to extensive and costly government regulation, including anti-kickback, fraud and abuse, and other healthcare laws, which could expose the company to significant liability.
• Internal computer systems, or those of contractors, may fail or experience security breaches, leading to disruptions, data loss, or legal liability.
• Failure to comply with data protection, privacy, and security laws and regulations could expose the company to liability.
• If intellectual property rights are not adequately protected, enforced, or secured, the value of intellectual property would diminish.
• Costly litigation may be necessary to protect intellectual property rights, and the company may be subject to claims alleging violation of others' intellectual property.
• Reliance on confidentiality agreements may be breached or difficult to enforce, allowing third parties to use intellectual property.
• International patent protection is uncertain, and involvement in opposition proceedings in foreign countries could be costly.
• Intellectual property rights may not address all potential threats to competitive advantage.
• May be subject to claims challenging the inventorship of patents and other intellectual property.
• May become subject to claims for remuneration or royalties for assigned service invention rights by employees.
• Terms and scope of patents may be insufficient to protect product candidates for an adequate period, allowing earlier competition.
• Operations in Israel expose the company to geopolitical, security, and economic conditions in the region, including ongoing armed conflicts and regional instability.
• Investors may have difficulties enforcing U.S. judgments against the company or its officers/directors in Israel.
• May not be able to enforce covenants not to compete under Israeli law, allowing former employees to benefit competitors.
• Shareholder rights and responsibilities are governed by Israeli law, which may differ from U.S. corporations.
• Changes in Israeli tax laws and examinations by Israeli Tax Authorities could increase overall tax liabilities.
• Provisions of Israeli law may delay, prevent, or impede mergers or acquisitions.
• Currency fluctuations and inflation may harm results of operations due to expenses incurred in NIS and Euros.
• Significant costs incurred as a U.S. public company, with management time devoted to compliance.
• Market price for ADSs has been and will likely remain volatile.
• Percentage ownership may be diluted by future issuances of share capital.
• If securities or industry analysts cease publishing research or publish negative reports, market price and trading volume could be negatively impacted.

Future Outlook

The company anticipates continued operating losses as its CDMO business unit is not yet profitable and R&D programs require ongoing investment. Future capital requirements are substantial and depend on the success of CDMO growth, R&D progress, and ability to secure additional non-dilutive and equity financing. The company plans to submit a revised FENG grant application for PC111 and expects a decision in July 2026, along with decisions on FENG applications for its IL-17 NanoAb programs. The IL-17 program's development strategy is under ongoing evaluation, which may lead to modifications or delays. The company aims to expand its CDMO business through new client acquisition and increased utilization, and its strategic collaboration with Recipharm is intended to support client programs through late-stage development.

Management Comments

• Management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made.
• Management estimates that there will be no future revenues from the M-001 product, and therefore no future royalty payments to the IIA.
• Management believes that the carrying value of the CDMO facility is appropriate as of the reporting date, based on an independent external valuation.
• Management believes that the company's business is supported by a combination of strategic, scientific and operational capabilities intended to enable advancement of its pipeline while managing development risk and capital constraints.
• Management believes that NanoAbs offer advantages such as strong binding affinity, thermal stability, and potential flexibility in routes of administration.

Industry Context

StockSavvy.ai notes that Scinai Immunotherapeutics' pivot to a dual R&D and CDMO business model reflects a broader industry trend among early-stage biopharmaceutical companies to diversify revenue streams and leverage existing infrastructure to mitigate high R&D costs and funding uncertainties. The focus on NanoAbs and monoclonal antibodies like PC111 aligns with the growing interest in targeted biologics for inflammatory and immunological diseases. However, the competitive landscape for IL-17 targeting therapies, with established players like Novartis and Lilly, presents significant market entry challenges for new monotherapies unless meaningful differentiation is demonstrated. The company's strategy of seeking non-dilutive funding through grants, similar to other European biotech firms, is a prudent approach to manage capital in a challenging funding environment. The acquisition of Recipharm Israel and the collaboration with Recipharm position Scinai to offer a more integrated service, competing with mid-tier CDMOs by providing a 'graduate' pathway for clients to larger manufacturing capabilities, a model increasingly sought after by emerging biotech companies.

Comparison to Industry Standards

• The competitive landscape for IL-17-targeting therapies is increasingly competitive, with multiple approved products and development-stage candidates from companies such as BMS, Novartis, Lilly, UCB, and Moonlake. Scinai's IL-17 NanoAb monotherapy may face significant commercial challenges unless it demonstrates meaningful differentiation compared to these established and pipeline therapies.
• For Pemphigus, PC111 competes with current first-line systemic corticosteroids and second-line biologics like Rituximab (Rituxan).
• For Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), there are currently no approved therapies aside from supportive care, suggesting a high unmet medical need that PC111 aims to address, potentially offering a significant advantage if successful in development.
• Scinai's CDMO business competes with established CDMOs that have greater resources, broader capabilities, and longer track records. Its success depends on demonstrating a superior value proposition, particularly in process technologies that improve efficiency and reduce costs/time in drug development projects.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently involved in any litigation that it believes could have a material adverse effect on its financial condition or results of operations.

Related Party Transactions

• Investment Commitment Agreement with RK Stone Miami LLC (an affiliate of Mr. Daniel Stone, the largest shareholder) in August 2024 for up to $2.0 million, resulting in the issuance of pre-funded warrants and commitment fees.
• Services agreement with Mr. Mark Germain (Chairman of the Board) for a monthly payment of $12,500, with a voluntary 20% reduction from mid-October 2024 to February 2025.
• Employment agreement with Mr. Amir Reichman (CEO) with an annual gross salary of $350,000, with a voluntary 25% reduction from mid-October 2024 to February 1, 2025, and eligibility for annual cash bonuses and RSU grants.
• Service agreement with CFO Direct (solely owned by Mr. Uri Ben-Or, CFO) for a monthly fee of NIS 40,000, plus an additional NIS 12,500 per month for nine months starting April 2026 for integration work.
• Employment agreement with Mr. Uri Ben-Or (CFO) for a 60% employment capacity with a monthly salary of NIS 10,000, and a cash bonus of $30,000 approved in October 2025.
• Employment agreement with Mr. Elad Mark (COO) with a monthly salary of NIS 55,000, with a 20% reduction from mid-October 2024 to December 31, 2024, and performance-based incentives and RSU grants.
• Indemnification agreements entered into with all current officers and directors, exculpating them to the fullest extent permitted by law and articles of association, and undertaking to indemnify them up to 25% of net assets.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing equity capital raises and potential loss of investment due to the 'going concern' doubt and volatile stock price. The proposed Nasdaq rule change regarding market value of listed securities poses an additional delisting risk. Preferred shareholders (EIB) have liquidation preference and certain veto rights over corporate actions.
• **Employees:** Subject to workforce disruptions due to geopolitical conflicts in Israel (military reserve duty). Management changes, including resignations of CSO and CTO, could impact R&D continuity. Compensation includes equity awards, linking their interests to company performance.
• **Customers (CDMO):** Benefit from expanded capabilities through the Recipharm Israel acquisition and the strategic collaboration, offering integrated development and manufacturing services across modalities. However, the CDMO unit's current operating losses and the company's 'going concern' status could raise concerns about long-term stability and service continuity.
• **Suppliers/Creditors:** The 'going concern' qualification and history of operating losses indicate increased credit risk. The EIB loan restructuring converted a large debt into preferred shares, reducing immediate debt obligations but establishing a new class of preferred shareholders with significant rights.
• **Regulatory Authorities:** The company's R&D and CDMO activities are subject to extensive and costly regulations (FDA, EMA, IIA, etc.). Delays in regulatory approvals or non-compliance could lead to sanctions and impact product commercialization.

Next Steps

• Submit a revised application to the FENG program for PC111 development by March 31, 2026, with a decision expected in July 2026.
• Await award decisions for two separate FENG grant applications for IL-17 NanoAb programs, expected in July 2026.
• Continue to evaluate the development strategy for the IL-17 NanoAb program, including formulation, delivery, and competitive positioning.
• Expand CDMO commercial activities, including negotiating additional contracts and increasing utilization of development and manufacturing capabilities.
• Integrate the acquired Recipharm Israel Ltd. operations into the existing CDMO business, including planned asset, operation, and employee transfers.
• Monitor compliance with Nasdaq listing rules, particularly the proposed rule change regarding market value of listed securities.
• Seek additional funding to support CDMO scale-up to breakeven and to continue research and development activities.
• Explore additional NanoAb licensing opportunities under existing collaborations with MPG and UMG.

Key Dates

Recommendation

The company explicitly states 'substantial doubt about our ability to continue as a going concern,' driven by recurring operating losses and insufficient cash to fund operations for the next year. While there are strategic initiatives like the CDMO expansion and new R&D programs, these are early-stage, loss-making, and heavily reliant on uncertain future financing. The repeated Nasdaq non-compliance issues and the potential for immediate delisting under a proposed new rule add significant regulatory risk. The high level of uncertainty regarding future funding, the early stage of product candidates, and the ongoing operational losses make the stock a high-risk investment with a strong likelihood of further value erosion.

Keywords

Biopharmaceutical, CDMO, NanoAbs, PC111, IL-17, Pemphigus, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Development, Clinical Trials, GMP Manufacturing, Orphan Drug, Israel Innovation Authority, Nasdaq Listing, Going Concern, Capital Raise, Biologics, Small Molecules, Immunology, Inflammation, Antibody Fragments